We generated adjusted earnings per share of $1.97 and strong cash flow from operations of $5.5 billion.
Adjusted earnings per share of $1.97 represent a nearly 19% year-over-year increase, generated by our adjusted operating income growth and lower interest expense resulting from our ongoing deleveraging efforts.
We generated adjusted earnings per share of $1.97 and strong cash flow from operations of $5.5 billion.
Adjusted earnings per share of $1.97 represent a nearly 19% year-over-year increase, generated by our adjusted operating income growth and lower interest expense resulting from our ongoing deleveraging efforts.
Given these results and our outlook, we are raising our adjusted earnings per share guidance to $7.90 to $8.
Total revenues of $73.8 billion increased 10% year over year with robust growth in all three segments.
We grew adjusted operating income by 12.5%.
In fact, this year, 12.5% of new COVID-19 testing customers chose to fill new prescriptions or receive a COVID-19 vaccination with CVS Health.
We reported adjusted operating income of $4.1 billion, a 12.5% increase versus the prior year.
Approximately half or $1.2 billion is attributable to the contributions from the more than 11 million COVID vaccines and over 8 million COVID tests we administered combined with strong front store sales driven by demand for over-the-counter COVID test kits and related treatment categories.
